These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34621001)

  • 1. Actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
    Chetruengchai W; Shotelersuk V
    J Hum Genet; 2022 Mar; 67(3):137-142. PubMed ID: 34621001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
    Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
    Maxwell KN; Hart SN; Vijai J; Schrader KA; Slavin TP; Thomas T; Wubbenhorst B; Ravichandran V; Moore RM; Hu C; Guidugli L; Wenz B; Domchek SM; Robson ME; Szabo C; Neuhausen SL; Weitzel JN; Offit K; Couch FJ; Nathanson KL
    Am J Hum Genet; 2016 May; 98(5):801-817. PubMed ID: 27153395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-frequency actionable pathogenic exome variants in an average-risk cohort.
    Rego S; Dagan-Rosenfeld O; Zhou W; Sailani MR; Limcaoco P; Colbert E; Avina M; Wheeler J; Craig C; Salins D; Röst HL; Dunn J; McLaughlin T; Steinmetz LM; Bernstein JA; Snyder MP
    Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30487145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and spectrum of actionable pathogenic secondary findings in 196 Korean exomes.
    Jang MA; Lee SH; Kim N; Ki CS
    Genet Med; 2015 Dec; 17(12):1007-11. PubMed ID: 25856671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of Secondary Findings in Chinese Population: A Practice of ACMG SF v3.0 List.
    Huang Y; Liu B; Shi J; Zhao S; Xu K; Sun L; Chen N; Tian W; Zhang J; Wu N
    J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The burden of pathogenic variants in clinically actionable genes in a founder population.
    Lynch MT; Maloney KA; Pollin TI; Streeten EA; Xu H; ; Shuldiner AR; Van Hout CV; Gonzaga-Jauregui C; Mitchell BD
    Am J Med Genet A; 2021 Nov; 185(11):3476-3484. PubMed ID: 34467620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of secondary genomic findings in the Saudi population.
    Aloraini T; Alsubaie L; Alasker S; Al Muitiri A; Alswaid A; Eyiad W; Al Mutairi F; Ababneh F; Alfadhel M; Alfares A
    Am J Med Genet A; 2022 Jan; 188(1):83-88. PubMed ID: 34515413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number alterations involving 59 ACMG-recommended secondary findings genes.
    Yatsenko SA; Aarabi M; Hu J; Surti U; Ortiz D; Madan-Khetarpal S; Saller DN; Bellissimo D; Rajkovic A
    Clin Genet; 2020 Dec; 98(6):577-588. PubMed ID: 33009833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of actionable secondary findings in 7472 Korean genomes derived from the National Project of Bio Big Data pilot study.
    Kim Y; Kim JM; Cho HW; Park HY; Park MH
    Hum Genet; 2023 Nov; 142(11):1561-1569. PubMed ID: 37728764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary ACMG and non-ACMG genetic findings in a multiethnic cohort of 16,713 pediatric participants.
    Saeidian AH; March ME; Youssefian L; Watson DJ; Bhandari E; Wang X; Zhao X; Owen NM; Strong A; Harr MH; ; Bhoj E; Zackai E; Vahidnezhad H; Gudjonsson JE; Cederbaum SD; Deignan JL; Glessner J; Grody WW; Hakonarson H
    Genet Med; 2024 Nov; 26(11):101225. PubMed ID: 39096151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actionable Genotypes and Their Association with Life Span in Iceland.
    Jensson BO; Arnadottir GA; Katrinardottir H; Fridriksdottir R; Helgason H; Oddsson A; Sveinbjornsson G; Eggertsson HP; Halldorsson GH; Atlason BA; Jonsson H; Oskarsson GR; Sturluson A; Gudjonsson SA; Thorisson GA; Zink F; Moore KHS; Palsson G; Sigurdsson A; Jonasdottir A; Jonasdottir A; Magnusson MK; Helgadottir A; Steinthorsdottir V; Gudmundsson J; Stacey SN; Hilmarsson R; Olafsson I; Johannsson OT; Arnar DO; Saemundsdottir J; Magnusson OT; Masson G; Halldorsson BV; Helgason A; Stefansson H; Jonsdottir I; Holm H; Rafnar T; Thorsteinsdottir U; Gudbjartsson DF; Stefansson K; Sulem P
    N Engl J Med; 2023 Nov; 389(19):1741-1752. PubMed ID: 37937776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study.
    Haverfield EV; Esplin ED; Aguilar SJ; Hatchell KE; Ormond KE; Hanson-Kahn A; Atwal PS; Macklin-Mantia S; Hines S; Sak CW; Tucker S; Bleyl SB; Hulick PJ; Gordon OK; Velsher L; Gu JYJ; Weissman SM; Kruisselbrink T; Abel C; Kettles M; Slavotinek A; Mendelsohn BA; Green RC; Aradhya S; Nussbaum RL
    BMC Med; 2021 Aug; 19(1):199. PubMed ID: 34404389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier frequency estimation of pathogenic variants of autosomal recessive and X-linked recessive mendelian disorders using exome sequencing data in 1,642 Thais.
    Chetruengchai W; Phowthongkum P; Shotelersuk V
    BMC Med Genomics; 2024 Jan; 17(1):9. PubMed ID: 38167091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
    Kalia SS; Adelman K; Bale SJ; Chung WK; Eng C; Evans JP; Herman GE; Hufnagel SB; Klein TE; Korf BR; McKelvey KD; Ormond KE; Richards CS; Vlangos CN; Watson M; Martin CL; Miller DT
    Genet Med; 2017 Feb; 19(2):249-255. PubMed ID: 27854360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced penetrance of pathogenic ACMG variants in a deeply phenotyped cohort study and evaluation of ClinVar classification over time.
    van Rooij J; Arp P; Broer L; Verlouw J; van Rooij F; Kraaij R; Uitterlinden A; Verkerk AJMH
    Genet Med; 2020 Nov; 22(11):1812-1820. PubMed ID: 32665702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A commentary on actionable secondary findings in the 73 ACMG-recommended genes in 1559 Thai exomes.
    Johnston JJ; Yoo S; Biesecker LG
    J Hum Genet; 2022 Oct; 67(10):617-619. PubMed ID: 35534676
    [No Abstract]   [Full Text] [Related]  

  • 18. PATH-SCAN: a reporting tool for identifying clinically actionable variants.
    Daneshjou R; Zappala Z; Kukurba K; Boyle SM; Ormond KE; Klein TE; Snyder M; Bustamante CD; Altman RB; Montgomery SB
    Pac Symp Biocomput; 2014; ():229-40. PubMed ID: 24297550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Abul-Husn NS; Amendola LM; Brothers K; Chung WK; Gollob MH; Gordon AS; Harrison SM; Hershberger RE; Klein TE; Richards CS; Stewart DR; Martin CL;
    Genet Med; 2022 Jul; 24(7):1407-1414. PubMed ID: 35802134
    [No Abstract]   [Full Text] [Related]  

  • 20. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
    Miller DT; Lee K; Chung WK; Gordon AS; Herman GE; Klein TE; Stewart DR; Amendola LM; Adelman K; Bale SJ; Gollob MH; Harrison SM; Hershberger RE; McKelvey K; Richards CS; Vlangos CN; Watson MS; Martin CL;
    Genet Med; 2021 Aug; 23(8):1381-1390. PubMed ID: 34012068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.